Lista de obras -

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

artículo científico publicado en 2015

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

artículo científico publicado en 2016

A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.

artículo científico publicado en 2014

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

artículo científico publicado en 2011

Analysis of miRNA, mRNA, and TF interactions through network-based methods.

artículo científico publicado en 2015

Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis

artículo científico publicado en 2020

DMETTM Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine

artículo científico publicado en 2020

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

artículo científico publicado en 2016

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

artículo científico publicado en 2012

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma

artículo científico publicado en 2015

Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.

artículo científico publicado en 2017

EDTA is essential to recover lead from dried blood spots on filter paper.

artículo científico publicado en 2004

Emerging pathways as individualized therapeutic target of multiple myeloma.

artículo científico

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

artículo científico publicado en 2017

Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells

artículo científico publicado en 2019

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

artículo científico

Functional Analysis of microRNA in Multiple Myeloma

artículo científico publicado en 2015

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy

artículo científico publicado en 2017

Genetic variants associated with gastrointestinal symptoms in Fabry disease.

artículo científico publicado en 2016

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

artículo científico publicado en 2015

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

artículo científico publicado en 2014

In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma

artículo científico publicado en 2014

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

artículo científico publicado en 2008

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

artículo científico publicado en 2015

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

artículo científico publicado en 2017

Mir-221/222 are promising targets for innovative anticancer therapy.

artículo científico publicado en 2016

Mir-34: a new weapon against cancer?

artículo científico

Molecular targets for the treatment of multiple myeloma.

artículo científico

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma ⬇️

artículo científico publicado el 1 de septiembre de 2012

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

artículo científico publicado en 2016

Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

artículo científico publicado en 2007

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

artículo científico publicado en 2020

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

artículo científico publicado en 2016

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma ⬇️

artículo científico publicado el 1 de septiembre de 2012

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.

artículo científico publicado en 2018

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

artículo científico publicado en 2015

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

artículo científico publicado en 2012

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

artículo científico publicado en 2014

The potential role of miRNAs in multiple myeloma therapy

artículo científico publicado en 2018

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

scientific article published on 11 July 2018

Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

artículo científico publicado en 2014

Uncharacterized RNAs in Plasma of Alzheimer's Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

artículo científico publicado en 2020

miR-22 suppresses DNA ligase III addiction in multiple myeloma

artículo científico publicado en 2018

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

artículo científico publicado en 2018

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

artículo científico publicado en 2013

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

artículo científico publicado en 2012

Lista de obras de

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

Analysis of miRNA, mRNA, and TF interactions through network-based methods.

Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis

DMETTM Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma

Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.

EDTA is essential to recover lead from dried blood spots on filter paper.

Emerging pathways as individualized therapeutic target of multiple myeloma.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

Functional Analysis of microRNA in Multiple Myeloma

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy

Genetic variants associated with gastrointestinal symptoms in Fabry disease.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Mir-221/222 are promising targets for innovative anticancer therapy.

Mir-34: a new weapon against cancer?

Molecular targets for the treatment of multiple myeloma.

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma ⬇️

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma ⬇️

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

The potential role of miRNAs in multiple myeloma therapy

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

Uncharacterized RNAs in Plasma of Alzheimer's Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

miR-22 suppresses DNA ligase III addiction in multiple myeloma

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1